Lung Cancer: Lung Cancer III |

Assessing Utility of Blood-Based Predictive and Prognostic Proteomic Test in Patient Non-small Cell Lung Cancer FREE TO VIEW

Valentine Ifeacho, MD; Prathamesh Prabhudesai, MD; Viola Zhu, MD; Daya Upadhyay, MD
Author and Funding Information

University of California San Francisco, Fresno, CA

Copyright 2016, American College of Chest Physicians. All Rights Reserved.

Chest. 2016;150(4_S):725A. doi:10.1016/j.chest.2016.08.820
Text Size: A A A
Published online


SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM

PURPOSE: Lung cancer is the most common cancer worldwide, and is the leading cancer killer in both men and women in the United States. The overall five-year survival rate for lung cancer continues to remain poor <18 percent. Therefore, there is a need for predictive biomarker tests that can identify which therapies are most appropriate for individual patients and assess their prognostic outcome. A Blood/Serum-based proteomic test veristrat by mass spectrometry has been used to predict outcomes of patients with non-small cell lung cancer (NSCLC). The test classifies the patients in the poor group have worse outcomes after treatment as compared to patients with the good group which respond to treatment. Although this test was initially developed for patients with EGFR mutation, given that the majority of NSCLC cases do not harbor activating mutations in the EGFR gene, utility of this test must be assessed in all patients with NSCLC. In this study, we examined the predictive and prognostic values of blood-based proteomic test in assessing disease progression and recurrence in lung cancer.

METHODS: Patients with newly diagnosed histological proven NSCLC were enrolled in the study. A Blood/Serum-based proteomic test was based on mass spectrometry. Clinical correlative analysis was performed to assess the predictive and prognostic values of this test.

RESULTS: Twenty seven patients with biopsy proven NSCLC were studied. Analysis of proteomic test showed 15% of our patient had prognostic test as poor, while 85% of our patient has the prognostic test as good. All of our patients in poor group were found to have disease progression and recurrence with sensitivity of 100% and specificity of 100% in predicting disease progression and recurrence.

CONCLUSIONS: Blood/serum-based proteomic test appears to have significantly high sensitivity and specificity in assessing disease progression and recurrence in lung cancer. Further, large scale studies are required to validate these findings and to assess clinical utility of this test in lung cancer.

CLINICAL IMPLICATIONS: The blood-based proteomic test may have a utility in assessing disease progression and recurrence in lung cancer.

DISCLOSURE: The following authors have nothing to disclose: Valentine Ifeacho, Prathamesh Prabhudesai, Viola Zhu, Daya Upadhyay

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543